



September 11, 2026

The National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex
Bandra (E) Mumbai - 400 051

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

Scrip code: STAR

Scrip code: 532531

Dear Madam/ Sir,

Reg: Disclosure under Regulation 30 of SEBI Listing Regulations

Sub: Completion of USFDA Inspection at the Company's Formulations Facility at Alathur

We hereby notify that a routine current Good Manufacturing Practices (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at the Company's Formulations Facility at Alathur, Chennai during the period **from September 2, 2026 to September 11, 2026**.

At the conclusion of the inspection, the USFDA has issued a Form 483 with three observations.

Company will respond to these observations to USFDA within the stipulated time.

We will keep the stock exchanges informed if there is any further update in this matter.

Please take the above information on record.

Thanks & Regards,

For **Strides Pharma Science Limited**,

Manjula Ramamurthy
Company Secretary
ICSI Membership No. A30515

Strides Pharma Science Limited

CIN: L24230MH1990PLC057062

Corp. Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru – 560 076, India | **Tel:** +91 80 6784 0000
Regd. Off: 'Cyber One', Unit No. 902, Plot No. 4&6, Sector 30A, Vashi, Navi Mumbai – 400 703, India | **Tel:** +91 22 2789 2924/3199
corpcomm@strides.com; www.strides.com